|
Public Health Dimensions of Epilepsy
|
Other
|
ACF, CDC, FDA, OS
|
NINDS, NIA, NICHD, NIMH
|
The Institute of Medicine will convene an ad hoc committee to recommend priorities in public health, healthcare and human services, and health literacy and public awareness for the epilepsies and to propose strategies to address these priorities.
|
|
Public Health Emergency Management Countermeasures Enterprise (PHEMCE)
|
Committee, Work group, Advisory group, or Task Force
|
ACF, CDC, FDA, OS, SAMHSA
|
NICHD, NIAID, NIAMS, NINDS, NLM
|
The NICHD representative is a regular member of the chemical working group and provides PRN assistance to the Infectious Disease and Radiation Working Groups. These groups determine medical countermeasures (MCM) requirements, reviews available and up and coming MCMs, makes advanced R&D study recommendations, funds recommended studies, funds some of the MCMs for the strategic national stockpile. The NICHD representative provides pediatric/OB input regarding MCM gaps, study needs, prioritization.
|
|
Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Chemical Requirements Working Group
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, OS
|
NINDS, NIAID, NICHD, NIEHS
|
The HHS Public Health Emergency Medical Countermeasures Enterprise (HHS PHEMCE) leads the mission to develop and acquire medical countermeasures that will improve public health emergency preparedness as well as prevent and mitigate the adverse health consequences associated with chemical, biological, radiological and nuclear (CBRN), and naturally occurring threats.
|
|
Public Health Information Network (PHIN)
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
NCI
|
The CDC Public Health Information Network (PHIN) is a national initiative to improve the capacity of public health to use and exchange information electronically by promoting the use of standards and defining functional and technical requirements.
|
|
Public Health Pesticide Consortium (PHPC)
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
NIAID
|
This group involves members from CDC and NIH as well as other federal US agencies ( USDA, EPA, DoD, USAID, HUD, and USFWS) with the purpose of learning about new programs and activities relating to the development and approval of pesticides for public health.
|
|
Public Health Prevention of HIV Risk Behaviors Technical Working Group
|
Committee, Work group, Advisory group, or Task Force
|
CDC, SAMHSA
|
NIAAA, NIDA
|
Collaboration with the Office of Global AIDS Coordination (OGAC), CDC to identify and implement effective HIV prevention and treatment interventions among alcohol abusing and dependent populations.
|
|
Public Health Service (PHS) Biovigilance Working Group
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA
|
NHLBI
|
The working group was formed to develop an operational proposal for enhancing safety monitoring for blood products, cell and tissue products, and solid organs.
|
|
Public Health Service (PHS) Blood XMRV Scientific Research Working Group
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA
|
NHLBI
|
The working group is charged with designing and coordinating research studies to evaluate whether xenotropic murine leukemia virus-related virus (XMRV) poses a threat to blood safety. The group is led by the NHLBI and includes representatives from the PHS, the FDA, and the CDC, as well as experts in research on transfusion medicine, blood banking, retrovirology, and myalgic encephalopathy/chronic fatigue syndrome.
|
|
Public Health Service (PHS) MSM Working Group
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA
|
NHLBI
|
The working group is developing guidelines and strategies to improve HIV/STD programs for men who have sex with men (MSM).
|
|
Public Health Service (PHS) Pathogen Reduction Taskforce
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA
|
NHLBI
|
As a part of the HHS strategic plan for blood and tissue safety, the taskforce is charged with reviewing the potential of pathogen reduction technologies that are designed inactivate pathogens in blood supply. Current surveillance systems detect threats, but the lag between detection and action continues to place recipients at risk. The taskforce seeks to address questions and challenges in transfusion safety, barriers to technological advancement, safety gaps related to pathogen reduction.
|